TAS-102 prolongs overall survival in refractory colorectal cancer, study showsBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2620 (Published 15 May 2015) Cite this as: BMJ 2015;350:h2620
- Susan Mayor
TAS-102, an oral drug that combines two agents to maintain blood levels of the active antitumour component, significantly prolongs survival in patients with metastatic colorectal cancer that is refractory to standard therapies, a phase III trial reported in the New England Journal of Medicine has shown.
Patients with colorectal cancer are routinely treated with fluoropyrimidines, which inhibit a key step …
Log in using your username and password
Log in through your institution
Sign up for a free trial